Anavex Life Sciences Corp.
Financials
Valuation Metrics
Anavex Life Sciences Corp.'s Market Cap is $105M. At end of 2025 it was $317M. Ranked #3048 of 3,116 in US market (top 98%), #1412 of 1,472 on NASDAQ (top 96%), #257 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $105M | US#3,048/3,116 Sec#257/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-24M | US—/3,116 Sec—/265 |
| Total Assets | $120M | US#3,037/3,116 Sec#256/265 |
| Net Assets | $112M | US#2,785/3,116 Sec#209/265 |
| Employees | 34 | US#2,728/3,116 Sec#215/265 |
| Value | ||
| P/B | 0.93x | US#468/3,116 Sec#23/265 |
| FCF Yield | -32.17% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -21.38% | US#2,492/3,116 Sec#101/265 |
| ROA | -20.01% | US#2,787/3,116 Sec#129/265 |
| Financial Health | ||
| Debt Ratio | 6.84% | US#60/3,116 Sec#30/265 |
| Total Debt | $0.00 | US—/3,116 Sec—/265 |
| FCF | $-34M | US#2,473/3,116 Sec#102/265 |
| Cash | $118M | US#2,105/3,116 Sec#159/265 |
| Current Ratio | 15.62x | US#158/3,116 Sec#47/265 |
| Performance | ||
| 1Y Return | -85.80% | US#3,096/3,116 Sec#259/265 |
| 1M Return | -37.82% | US#3,084/3,116 Sec#261/265 |
| From 52W High | -85.47% | US#3,078/3,116 Sec#256/265 |
| 1Y MDD | -84.85% | US#3,072/3,116 Sec#253/265 |
| Trading | ||
| Volume | 1,005,771 shares | US#1,582/3,116 Sec#158/265 |
| Trading Value | $1M | US#3,004/3,116 Sec#253/265 |
| Per Share | ||
| EPS | $-0.26 | US—/3,116 Sec—/265 |
| BPS | $1.21 | US#2,660/3,116 Sec#195/265 |
Company Info
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.